237,726 Shares in Harmony Biosciences Holdings, Inc. $HRMY Acquired by Tieton Capital Management LLC

Tieton Capital Management LLC acquired 237,726 shares of Harmony Biosciences, valued at $7.5 million, making it 3.1% of their holdings. Analysts have mixed ratings, with a Moderate Buy consensus and an average price target of $44.63. Harmony Biosciences reported Q3 earnings of $0.87 per share, missing estimates, with revenue of $239.46 million. The stock opened at $34.31, with a market cap of $1.98 billion.

Tieton Capital Management LLC acquired a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 237,726 shares of the company's stock, valued at approximately $7,512,000. Harmony Biosciences makes up about 3.1% of Tieton Capital Management LLC's holdings, making the stock its 16th biggest position. Tieton Capital Management LLC owned about 0.41% of Harmony Biosciences as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of HRMY. Brooklyn Investment Group boosted its position in shares of Harmony Biosciences by 1,031.9% during the first quarter. Brooklyn Investment Group now owns 1,064 shares of the company's stock worth $35,000 after acquiring an additional 970 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in Harmony Biosciences by 4,185.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company's stock valued at $37,000 after acquiring an additional 1,130 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Harmony Biosciences in the 1st quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Harmony Biosciences by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company's stock valued at $70,000 after purchasing an additional 299 shares during the last quarter. Finally, CWM LLC grew its position in shares of Harmony Biosciences by 34.8% during the first quarter. CWM LLC now owns 2,704 shares of the company's stock valued at $90,000 after purchasing an additional 698 shares in the last quarter. Institutional investors own 86.23% of the company's stock.

Get Harmony Biosciences alerts:

Wall Street Analyst Weigh In

HRMY has been the topic of a number of research analyst reports. Mizuho boosted their target price on Harmony Biosciences from $36.00 to $39.00 and gave the stock an "outperform" rating in a research report on Thursday, November 6th. UBS Group reduced their price objective on Harmony Biosciences from $50.00 to $43.00 and set a "buy" rating on the stock in a research note on Wednesday, October 15th. Weiss Ratings reiterated a "hold (c)" rating on shares of Harmony Biosciences in a research report on Monday, November 17th. Oppenheimer reissued an "outperform" rating and issued a $62.00 target price on shares of Harmony Biosciences in a report on Monday. Finally, Needham & Company LLC decreased their price target on shares of Harmony Biosciences from $48.00 to $41.00 and set a "buy" rating on the stock in a research note on Wednesday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $44.63.

View Our Latest Stock Report on HRMY

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $34.31 on Monday. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of 10.79, a PEG ratio of 0.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.75 and a quick ratio of 3.72. The business has a 50 day simple moving average of $29.67 and a 200-day simple moving average of $32.97. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.93.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.05). The company had revenue of $239.46 million for the quarter, compared to the consensus estimate of $222.68 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. Equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

About Harmony Biosciences

(Free Report)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Should You Invest $1,000 in Harmony Biosciences Right Now?

Before you consider Harmony Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.

While Harmony Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

237,726 Shares in Harmony Biosciences Holdings, Inc. $HRMY Acquired by Tieton Capital Management LLC

Wall Street Analyst Weigh In

Harmony Biosciences Price Performance

About Harmony Biosciences

Further Reading

Should You Invest $1,000 in Harmony Biosciences Right Now?